Nucleai

There are 150+ ADCs in a hyper-competitive clinical pipeline, where success increasingly hinges on finding the right patients - and biomarker-led trials roughly double the probability of success from Phase 1 to BLA (~8% → ~16%). That's the problem Nucleai solves, with a track record across ADC clinical programs to prove it.

Nucleai is the AI-powered tissue-intelligence layer for biopharma drug development. We turn pathology into predictive biomarkers and QMS-grade clinical analysis - quantifying the tumor heterogeneity, spatial proximity, and bystander effect that current methods miss - with a delivery record across ADC trials and companion-diagnostic development. We help pharma teams identify ultra-responders, de-risk trial design, and win where it matters most: ADCs, radiopharmaceuticals, and bispecifics.

This is a senior, individual-contributor closing role for someone who already sells at the intersection of oncology science and pharma R&D - not a team to manage, and not a role you grow into. We have strong pipeline and warm access at major accounts; your job is to convert those conversations into signed, scoped engagements, with people who already know and trust you.

What you'll do

• Close. Own signed bookings across ADC, radiopharma, and bispecific programs. Your number is contracts, not meetings.
• Convert relationships into scoped, paid engagements - moving deals from first conversation to signed SOW with our scientific and delivery teams.
• Bring and activate your network: engage translational, biomarker, and clinical-development leaders you already know, and turn them into pipeline fast.
• Run the full cycle with real qualification discipline - scoping, proposal, negotiation, close (we run MEDDIC).
• Be the internal commercial voice of the ADC market.

What you bring

• 5+ years selling directly to pharma/biopharma R&D (translational, biomarker, or clinical development), typically 10+ years in commercial roles. The 5+ years selling directly to pharma/biopharma R&D is a hard requirement - general enterprise, medtech, or provider/health-system sales does not substitute.
• A warm ADC/oncology rolodex - current, trusted relationships with translational, biomarker, and clinical-development leaders at ADC developers. This is the heart of the role.
• A proven record in services and project-based engagements - not product or SaaS. You've sold bespoke, scoped analytical work the buyer has to envision before they buy (Foundation Medicine, Tempus, NeoGenomics, CellCarta, Caris, or a CRO translational/biomarker unit is exactly the right background).
• A credible life-sciences foundation - you can hold a real conversation about tumor biology, biomarkers, and IHC, and translate the science into commercial value.
• Consultative selling, executive presence, and the stamina for long, scientifically sophisticated cycles.

This role is not a fit if you're a generalist sales leader looking to move into life sciences, a broad "healthcare/health-system" director without pharma R&D selling, early in your commercial career, or looking for a management seat. We're hiring one senior closer with the network and scientific fluency to own this segment from day one.

Why Nucleai

Work at the frontier of AI and precision oncology on some of the most important problems in drug development - with warm accounts to convert, science behind every conversation, and the autonomy to own this segment. Remote, US-based.

• Interested, or know someone who closes at this level? Reach out directly. 🧬